Cerulean Pharma Company Profile (NASDAQ:DARE)

About Cerulean Pharma (NASDAQ:DARE)

Cerulean Pharma logoDare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women's reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Industry, Sector and Symbol:
  • Sector: Finance
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DARE
  • CUSIP: N/A
  • Web: www.darebioscience.com
  • Market Cap: $16.93 million
  • Outstanding Shares: 2,903,000
Average Prices:
  • 50 Day Moving Avg: $4.87
  • 200 Day Moving Avg: $7.60
  • 52 Week Range: $2.63 - $35.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.19
  • P/E Growth: 0.00
  • Return on Equity: -244.69%
  • Return on Assets: -99.67%
  • Current Ratio: 2.43%
  • Quick Ratio: 2.34%
  • Average Volume: 175,083 shs.
  • Beta: 2.56

Frequently Asked Questions for Cerulean Pharma (NASDAQ:DARE)

What is Cerulean Pharma's stock symbol?

Cerulean Pharma trades on the NASDAQ under the ticker symbol "DARE."

How were Cerulean Pharma's earnings last quarter?

Cerulean Pharma Inc. (NASDAQ:DARE) released its quarterly earnings data on Thursday, August, 4th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.08. View Cerulean Pharma's Earnings History.

When will Cerulean Pharma make its next earnings announcement?

Cerulean Pharma is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Cerulean Pharma.

Where is Cerulean Pharma's stock going? Where will Cerulean Pharma's stock price be in 2017?

4 brokerages have issued 1-year target prices for Cerulean Pharma's shares. Their predictions range from $1.50 to $6.00. On average, they anticipate Cerulean Pharma's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for Cerulean Pharma.

Who are some of Cerulean Pharma's key competitors?

Who are Cerulean Pharma's key executives?

Cerulean Pharma's management team includes the folowing people:

  • Roger L. Hawley, Independent Chairman of the Board
  • Sabrina Martucci Johnson, President, Chief Executive Officer, Secretary, Director
  • Gregg D. Beloff J.D., Principal Financial Officer
  • Lisa Walters-Hoffert, Chief Financial Officer
  • Jame O'Neill, Principal Accounting Officer, Controller, Assistant Treasurer
  • William H. Rastetter Ph.D., Lead Independent Director
  • Steve E. Hall Ph.D., Independent Director
  • Susan L. Kelley M.D., Independent Director
  • Robin J. Steele J.D., Independent Director

How do I buy Cerulean Pharma stock?

Shares of Cerulean Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerulean Pharma's stock price today?

One share of Cerulean Pharma stock can currently be purchased for approximately $2.76.

MarketBeat Community Rating for Cerulean Pharma (NASDAQ DARE)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  205
MarketBeat's community ratings are surveys of what our community members think about Cerulean Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cerulean Pharma (NASDAQ:DARE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $3.00 (8.70% upside)

Analysts' Ratings History for Cerulean Pharma (NASDAQ:DARE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/9/2016Canaccord GenuityReiterated RatingBuy$6.00N/AView Rating Details
10/23/2016Roth CapitalReiterated RatingBuy$2.50N/AView Rating Details
10/19/2016Leerink SwannReiterated RatingMarket Perform$1.50N/AView Rating Details
8/30/2016Barclays PLCLower Price TargetOverweight$5.00 -> $2.00N/AView Rating Details
8/18/2016WedbushDowngradeOutperform -> NeutralN/AView Rating Details
8/18/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
3/9/2016J P Morgan Chase & CoBoost Price TargetMarket Outperform$9.00 -> $16.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $9.00N/AView Rating Details
(Data available from 8/19/2015 forward)


Earnings History for Cerulean Pharma (NASDAQ:DARE)
Earnings by Quarter for Cerulean Pharma (NASDAQ:DARE)
Earnings History by Quarter for Cerulean Pharma (NASDAQ DARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.48)($0.40)ViewN/AView Earnings Details
5/2/2016Q116($0.43)($0.49)ViewN/AView Earnings Details
3/10/2016Q415($0.41)($0.39)ViewListenView Earnings Details
11/16/2015Q315($0.41)($0.39)ViewListenView Earnings Details
8/6/2015Q215($0.40)($0.37)ViewN/AView Earnings Details
3/19/2015Q4 2014($0.36)($0.37)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.32)($0.28)ViewN/AView Earnings Details
8/12/2014Q2 2014($0.36)($0.34)$0.03 millionViewN/AView Earnings Details
5/27/2014Q1 2014($3.52)($3.70)$0.05 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cerulean Pharma (NASDAQ:DARE)
Current Year EPS Consensus Estimate: $-14.2 EPS
Next Year EPS Consensus Estimate: $-14.3 EPS


Dividend History for Cerulean Pharma (NASDAQ:DARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cerulean Pharma (NASDAQ:DARE)
Insider Ownership Percentage: 28.60%
Insider Trades by Quarter for Cerulean Pharma (NASDAQ:DARE)
Insider Trades by Quarter for Cerulean Pharma (NASDAQ:DARE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016David R WaltDirectorBuy2,291$2.08$4,765.28View SEC Filing  
2/18/2016David R. WaltDirectorBuy8,960$2.10$18,816.00View SEC Filing  
2/16/2016David R. WaltDirectorBuy8,811$2.00$17,622.00View SEC Filing  
2/11/2016David R. WaltDirectorBuy8,850$2.05$18,142.50View SEC Filing  
2/9/2016David R. WaltDirectorBuy9,000$2.15$19,350.00View SEC Filing  
2/5/2016David R. WaltDirectorBuy8,563$2.30$19,694.90View SEC Filing  
2/3/2016David R. WaltDirectorBuy8,413$2.32$19,518.16View SEC Filing  
2/1/2016David R. WaltDirectorBuy5,700$2.38$13,566.00View SEC Filing  
1/28/2016David R. WaltDirectorBuy9,000$2.46$22,140.00View SEC Filing  
1/26/2016David R. WaltDirectorBuy8,800$2.39$21,032.00View SEC Filing  
1/25/2016David R. WaltDirectorBuy4,500$2.35$10,575.00View SEC Filing  
1/22/2016David R. WaltDirectorBuy9,000$2.28$20,520.00View SEC Filing  
1/20/2016David R. WaltDirectorBuy8,900$2.43$21,627.00View SEC Filing  
1/15/2016David R. WaltDirectorBuy8,572$2.53$21,687.16View SEC Filing  
1/13/2016David R. WaltDirectorBuy8,684$2.79$24,228.36View SEC Filing  
1/11/2016David R. WaltDirectorBuy8,855$2.87$25,413.85View SEC Filing  
1/7/2016David R. WaltDirectorBuy8,800$2.95$25,960.00View SEC Filing  
1/5/2016David R. WaltDirectorBuy8,801$3.03$26,667.03View SEC Filing  
11/30/2015David R WaltDirectorBuy5,374$3.25$17,465.50View SEC Filing  
11/27/2015David R. WaltDirectorBuy12,117$3.32$40,228.44View SEC Filing  
4/7/2015Cvf, LlcMajor ShareholderBuy333,333$6.00$1,999,998.00View SEC Filing  
4/15/2014Alan L CraneDirectorBuy1,470,582$7.00$10,294,074.00View SEC Filing  
4/15/2014Eli & Co LillyMajor ShareholderBuy733,445$7.00$5,134,115.00View SEC Filing  
4/15/2014Lux Capital Management, LlcInsiderBuy106,224$7.00$743,568.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cerulean Pharma (NASDAQ:DARE)
Latest Headlines for Cerulean Pharma (NASDAQ:DARE)



Cerulean Pharma (DARE) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by MarketBeat.com Staff